• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

Jazz Pharma Breaks Ground on New Manufacturing Facility

February 14, 2014 by admin

Jazz Pharmaceuticals has commenced construction on a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon, approximately 75 miles east of the company’s Dublin, Ireland, headquarters. This is the first manufacturing facility to be built by Jazz Pharmaceuticals.

“Today marks a milestone for Jazz Pharmaceuticals as we break ground in Ireland and begin, for the first time, construction on a manufacturing and development facility,” said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals plc. “This investment not only strengthens our international manufacturing capabilities, but importantly represents our commitment to expanding our presence in Ireland. We are grateful for the partnership of Ireland’s Industrial Development Authority and Roscommon County Council who helped make this project possible.”

Members of the Board of Directors and employees of Jazz Pharmaceuticals were joined by the Taoiseach (Prime Minister) of Ireland, Enda Kenny TD and Barry O’Leary, CEO, Ireland’s Industrial Development Authority (IDA Ireland), during a ground-breaking ceremony earlier this week. The anticipated completion date for the 55,00-sq-ft facility is in 2016.

Jazz Pharmaceuticals expects to invest approximately $60 – $68 million in construction, development and personnel costs to build and open the facility. The investment is being supported by the Irish Government’s Department of Jobs, Enterprise and Innovation through IDA Ireland.

“Jazz Pharmaceuticals’ decision to build a manufacturing site in Ireland is testament to the excellent reputation Ireland has as a global location for biopharmaceutical development and manufacturing,” said O’Leary, CEO IDA Ireland. “This is a strategically important development for Jazz Pharmaceuticals and Ireland is well placed to support manufacturing for the company’s growing commercial portfolio.

Filed Under: Articles, Blog

Primary Sidebar

More to See

Xywav Oral Solution for Idiopathic Hypersomnia

February 16, 2022 By Alan Hickey

New Insomnia Drug Improves Sleep Outcomes for Adults

February 10, 2022 By Alan Hickey

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • Sleep Hygiene: Which Bedroom Colors to Avoid and which Promote Good Sleep??
  • Xywav Oral Solution for Idiopathic Hypersomnia
  • New Insomnia Drug Improves Sleep Outcomes for Adults
  • Mark Cuban Billionaire Entrepreneur and Television Personality Launches Online Pharmacy for Generic Drugs
  • Americans Say They’re Sleep-Deprived After the Super Bowl

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2022 · Sleep Diagnosis and Therapy